Back to the Future: How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

Back to the Future: How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

Episodes

Specialty:

All

Year:

All

EP. 1: How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

ByDavid L. Porter, MD, University of Pennsylvania,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Elizabeth Budde, MD, PhD

October 16th 2020

Trending on OncLive

Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC

T-DXd Improves PFS in First-Line HER2-Mutant NSCLC

FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer

Adding SBRT to Nivolumab/Ipilimumab Fails to Improve Outcomes in mCRPC

Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer